The funding is part of a €10 million round to accelerate the development of AI-based solutions for cancer prevention.
Health Triage, an innovative startup operating in the digital health sector, has announced the closing of a €5 million investment from the ENEA Tech and Biomedical Foundation. The transaction is part of a broader €10 million investment round aimed at accelerating the development and deployment of artificial intelligence technologies for early cancer diagnosis.
Founded in 2020 by Raffaele Petrone and Davide Dettori, Health Triage is based in Turin – in which the start-up successfully completed an incubation path in I3P, the Innovative Companies Incubator of Politecnico di Torino – and Pozzuoli (Naples). The company is a concrete example of high-impact technological innovation developed within the national territory, with a particular focus on supporting excellence in Southern Italy.
Health Triage’s technologies
The startup is currently developing two flagship solutions:
- BreastNegative.ai is a software platform designed to support radiologists in reading mammograms, enabling a more efficient management of breast cancer screening programs. Since over 99% of mammograms return negative results, the system acts as a “first reader” to prioritize the most relevant cases. When its reading aligns with the radiologist’s, the second reading can be avoided—cutting time and costs.
- VirtualBiopsy.ai is a cutting-edge technology for prostate cancer diagnosis, offering the first non-invasive virtual biopsy. Based on AI algorithms and radiomics, it provides a binary assessment of cancer presence and estimates tumor aggressiveness. This solution helps reduce the need for invasive biopsies, which fail to detect cancer in about 30% of first attempts, thereby preventing overdiagnosis and unnecessary treatments.
Research partnerships and development plans
To ensure the clinical validation of its solutions, Health Triage collaborates with leading academic and medical institutions such as the Politecnico and University of Turin, the Candiolo Cancer Prevention Foundation, the Italian Society of Urology (SIU), GISMa, and the Humanitas group.
Statements
“We are proud to welcome the ENEA Tech and Biomedical Foundation as an investor that shares our vision of innovation as a driver to improve access to cancer prevention,” said Davide Dettori, CEO and co-founder of Health Triage. “This investment will allow us to strengthen our team, expand our R&D activities, and start scaling our solutions at the international level.”
